-
Electronic (PDF)
-
Site License
-
Enterprisewide
Hyper Acute Pancreas (Pancreatic Cancer) - Analysis and Forecasts to 2020
GlobalData, December 2011, Pages: 25
Hyper Acute Pancreas (Pancreatic Cancer) - Analysis and Forecasts to 2020
Summary
GlobalData’s pharmaceuticals report, “Hyper Acute Pancreas (Pancreatic Cancer) - Analysis and Forecasts to 2020” provides Hyper Acute Pancreas sales forecasts for the US. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2015-2020). The report also includes information on Pancreatic Cancer market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.
Scope
- Therapy area profile including patient population for the US
- Analysis and review of Hyper Acute Pancreas including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Hyper Acute Pancreas including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecasts for 2015-2020 for Hyper Acute Pancreas in the US
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Keywords
HyperAcute Pancreas, HAPa, Pancreatic Cancer, IGF-1R, Sales forecast, vaccine, phase III, phase 3, pipeline, GVAX, HyperAcute Pancreas, Irinotecan, Sutent, GV1001, Afinitor, Avastin, AMG479, Abraxane, Masitinib, Gemzar, Nexavar, S-1, Tarceva, Certican, NewLink Genetics
1
1
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Pancreatic Cancer
2.2 Pancreatic Cancer Market
2.3 Epidemiology
2.4 Etiology
2.5 The Main Recognized Risk Factors
2.5.1 Cigarette Smoking
2.5.2 Age
2.5.3 Gender
2.5.4 Family History
2.5.5 Other Factors
2.5.6 Pancreatic Cancer Prevention
2.6 GlobalData Report Guidance
3 Pancreatic Cancer: Market Characterization
3.1 Pancreatic Cancer Disease Market
3.2 Pancreatic Cancer Disease Market Forecasts and CAGR
3.3 Drivers for the Pancreatic Cancer Disease Market
3.3.1 High Incidence
3.3.2 Large Unmet Need
3.3.3 Active Pipeline
4 Tumor-Node-Metastases (TNM) Classification of Pancreatic Cancer
4.1 Treatment Options in Pancreatic Cancer
4.2 Classification of Patients with Pancreatic Cancer
5 HyperAcute Pancreas
5.1 Introduction
5.2 Mechanism of Action
5.3 Clinical Studies
5.4 Factors Affecting Sales of HyperAcute Pancreas
5.4.1 Newly Emerging Therapeutic Area – Therapeutic Cancer Vaccine
5.4.2 First Mover Advantage
5.4.3 Absence in EU and Japan
5.4.4 Low Toxicity
5.5 Drug Risk Benefit Score
5.5.1 Efficacy
5.5.2 Safety
5.5.3 Compliance
5.5.4 Dosing Convenience
5.6 Intensity of Competition
5.7 Sales Forecasts
5.7.1 Target Patient Pool of HyperAcute Pancreas
5.7.2 Dosing
5.7.3 Market Penetration
5.7.4 Annual Cost of Therapy
5.7.5 Sales Projections of HyperAcute Pancreas
6 Appendix
6.1 Market Definitions
6.2 Abbreviations
6.3 Research Methodology
6.3.1 Coverage
6.3.2 Secondary Research
6.3.3 Forecasting
6.3.4 Number of Patients Approved to Take the Drug
6.3.5 Net Penetration of Drug
6.3.6 Net Annual Dosing
6.3.7 Annual Cost of Therapy
6.4 Drug Sales Estimates Model
6.5 Contact Us
6.6 Disclaimer
6.7 Sources
1.1 List of Tables
Table 1: Pancreatic cancer, Estimated Incidence and Mortality, 2008–2030
Table 2: Pancreatic Cancer, TNM Classification
Table 3: Drug Risk Benefit Score of Hyperacute Pancreas
Table 4: HyperAcute Pancreas, Pancreatic Cancer, The US, Sales Forecasts ($m), 2015-2020
1.2 List of Figures
Figure 1: Worldwide Incidence and Mortality Distribution of Top 20 Cancers (%), 2008
Figure 2: Total number of cigarettes consumed, The US, 1976-2006
Figure 3: Average Incidence Rate per 100,000, Pancreatic Cancer, the US, Both Sexes, 1992–2007
Figure 4: Incidence Rate per 100000, Pancreatic Cancer, the US, Both Sexes, 2010–2030
Figure 5: Pancreatic Cancer, Global, Market Size Forecasts ($m), 2010–2020
Figure 6: Pancreatic Cancer, Worldwide, Incidence (in million), 2008-2030
Figure 7: Oncology, Worldwide, Incidence (in million), 2008-2030
Figure 8: Broad Classification of Pancreatic Cancer
Figure 9: Classification of Patients with Pancreatic Cancer
Figure 10: Drug Model Diagram of HyperAcute Pancreas
Figure 11: HyperAcute Pancreas, Pancreatic Cancer, The US, Sales Forecasts ($m), 2015-2020
Figure 12: Patients Approved for the Drug
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
